Neratinib for Metastatic HER2+ Breast Cancer and Brain Metastases

Video

Oncologists debate the use of neratinib for metastatic HER2+ breast cancer treatment in the context of the HER2CLIMB clinical trial data on tucatinib.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content